5 Fu

Quick links to important sections

5 Fu

Method of action: Antiemetic, Antitumour, Cytostatic

Treatment option: Cancer

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of 5 Fu

Property Description
Active ingredient Fluorouracil (5-FU)
Form Solution for injection, Topical cream
Pharmacological class Antineoplastic Antimetabolite
General purpose Disrupts the growth of abnormal cells
Origin Synthetic compound

5-Fluorouracil (5-FU), formally designated as Fluorouracil, is a potent, synthetic compound classified as a nucleoside metabolic inhibitor. It functions specifically as an antimetabolite, which is a type of chemotherapy agent designed to disrupt a cell's ability to produce or repair its genetic material. It acts as a key cytotoxic agent and a pyrimidine analog. Fluorouracil closely mimics the natural molecule uracil, a unique chemical strategy essential to its efficacy within oncological treatment. Its use is widely recognized in clinical oncology settings, distinguishing it as a foundational medicine in chemotherapy protocols.

Forms and Composition of 5-Fluorouracil

The active ingredient, Fluorouracil, is a single-component product available in two primary dosage forms: a sterile solution for injection for intravenous use and a topical cream preparation. The solution utilizes an aqueous base for systemic delivery, while the topical cream employs an emollient base to concentrate the drug's effect locally on the skin's surface. Fluorouracil is a critical component used both systemically and locally to manage abnormal cell proliferation. This dual availability of both injectable and cream forms offers a crucial distinction, providing flexibility in clinical application compared to agents restricted to a single route.

The General Therapeutic Purpose of 5-FU

The general purpose of 5-FU is to inhibit the creation of new, faulty genetic material, effectively slowing or halting the multiplication of abnormal cells. When absorbed, this cytotoxic medicine interferes with the metabolic pathways necessary for DNA synthesis, specifically by blocking the enzyme thymidylate synthase. This action serves as a foundational strategy in disrupting the uncontrolled growth characteristic of malignant neoplasms, providing a standard approach in addressing rapidly proliferating tissue.

What side effects are possible with 5 Fu?

Possible Side Effects and Safety Information

Fluorouracil's official safety profile is defined by specific adverse reactions, classified by frequency and affected organ system, as documented in regulatory sources.

General Systemic Safety and Serious Adverse Reactions

Myelosuppression (a decrease in blood cell production) and gastrointestinal toxicities (such as severe diarrhea and mucositis) are classified as very common adverse reactions. Serious and potentially fatal adverse reactions include profound myelosuppression and specific manifestations of cardiotoxicity (e.g., myocardial ischemia, sudden cardiac death). Another serious adverse reaction documented is hyperammonemic encephalopathy, which can occur within 72 hours of treatment initiation.

Organ System Effects and Frequency

System-Organ Class Frequency Classification Examples of Reactions
Blood and Lymphatic Very Common Neutropenia, Leukopenia
Gastrointestinal Very Common Stomatitis, Diarrhea, Vomiting
Cardiac Disorders Very Common to Rare Ischaemic ECG changes, Arrhythmia, Myocardial Infarction
Skin and Subcutaneous Very Common Alopecia, Palmar-Plantar Erythrodysesthesia

Safety Considerations and Restrictions

Safety is significantly constrained by metabolic factors. Patients with a known complete deficiency of the DPD enzyme (Dihydropyrimidine Dehydrogenase) are at an extremely high risk for acute, fatal toxicity, and use is generally not recommended in this population. The medicine is also typically contraindicated for women who are pregnant or breastfeeding due to the risk of fetal harm. Furthermore, the risk of cardiotoxicity is officially noted to be more common in patients receiving continuous infusion compared to bolus injection.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with 5-Fluorouracil (5-Fu) is a severe, life-threatening medical emergency primarily defined by its potential for profound systemic toxicity, as documented in regulatory labeling.

Documented Overdose Manifestations

Official regulatory sources cite that an overdose or severe, early-onset toxicity is characterized by several critical signs affecting multiple organ systems:

  • Hematopoietic System: Severe and potentially fatal myelosuppression, including neutropenia and thrombocytopenia.
  • Gastrointestinal Tract: Severe mucositis, stomatitis, and potentially hemorrhagic diarrhea.
  • Central Nervous System (CNS): Acute neurotoxicity, such as cerebellar syndrome or hyperammonemic encephalopathy.
  • Cardiovascular System: Cardiotoxicity, including angina and myocardial ischemia.

Required Emergency Actions

Immediate and urgent medical attention is required upon suspicion of an overdose or development of early-onset, severe toxicities. The official response involves two key steps:

  1. Immediate Discontinuation: The 5-Fu infusion must be immediately withheld and permanently discontinued.
  2. Antidote Administration: The specific antidote, Uridine Triacetate, is approved for emergency treatment following a 5-Fu overdose. For efficacy, this treatment is generally mandated to be initiated within 96 hours after the end of the 5-Fu administration.

Therapeutic Uses of 5 Fu

What 5-FU Treats: Main Uses and Benefits

The primary therapeutic role of Fluorouracil (5-FU) is to provide anti-proliferative support in conditions generally characterized by uncontrolled cell growth, covering both systemic malignancies and localized skin abnormalities.

Clinical Contexts and Patient Benefit

This therapy is commonly used in the management of cancers arising in the gastrointestinal tract, including colorectal, gastric, and pancreatic adenocarcinoma, as well as certain forms of breast cancer. The medication is applied to address the symptomatic cluster of uncontrolled cellular proliferation by helping address the growth of abnormal cells. This strategic use, often in combination protocols, plays a role in managing the overall symptom load and supports the patient during difficult episodes of advanced or high-risk disease. The medication is also relevant in specialized clinical settings, such as adjuvant and neoadjuvant therapy, to assist with treatment prior to or following surgery.

“The treatment approach is designed to manage the overall burden of symptoms associated with these conditions.”

The topical formulation is generally used to help with the clearance of actinic keratoses and certain superficial basal cell carcinomas. The benefit supports the patient by helping address these abnormal skin cells, which is relevant for managing conditions where symptoms may intensify temporarily.


Quick Fact: Relief for Uncontrolled Cell Growth

Fluorouracil is commonly used for managing conditions that involve both systemic solid tumors (gastrointestinal and breast) and localized skin abnormalities (pre-malignant lesions), providing supportive relief across both therapeutic domains.

Regulatory References

  1. MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Who Can and Cannot Use 5-Fu?

The eligibility for Fluorouracil (5-FU) is strictly defined by regulatory guidelines to prevent severe toxicity. The medication is generally intended for use in adults diagnosed with the approved systemic malignancies or specific localized skin conditions, such as actinic keratoses.

Absolute Non-Eligibility (Contraindications)

According to official regulatory labeling, Fluorouracil is absolutely contraindicated for use in several populations:

Population Status Restriction Reason
Complete DPD Deficiency Life-threatening or fatal toxicity risk
Pregnancy and Lactation Fetal harm risk; unknown risk to nursing infant
Concomitant Brivudine Use Severe drug interaction risk
Serious Systemic Issues Serious infections; severe liver impairment; seriously debilitated state

Restricted and Conditional Use

Use is subject to conditional restrictions for several populations, requiring heightened caution or dose modification, which must be determined by a healthcare provider:

  • Partial DPD Deficiency: Patients face an increased risk of toxicity, and no safe dose has been established by regulators.
  • Organ Impairment: Caution is advised, and dose adjustment may be necessary for patients with impaired hepatic (liver) or renal (kidney) function.
  • Age: Use in pediatric patients (children and adolescents) is not recommended because safety and effectiveness have not been established.
  • Geriatric Patients: Older adults may use the medication but require special care due to potential susceptibility to toxicities.

What should I know about interactions with other medicines?

Interactions with other Medicines and Products

Official regulatory information for Fluorouracil (5-FU) highlights specific drug combinations that carry a risk of significantly altered exposure or additive toxicities.

Contraindicated Combinations and Timing Restrictions

The co-administration of 5-FU with Brivudine, Sorivudine, or their chemically related analogues is formally contraindicated by regulatory bodies. These agents inhibit the enzyme Dihydropyrimidine Dehydrogenase (DPD), which is essential for 5-FU clearance. This inhibition can lead to dangerously increased 5-FU systemic exposure and potential toxicity. An officially documented mandatory separation period of at least four weeks (28 days) must elapse between the use of these DPD inhibitors and the administration of 5-FU.

Clinically Significant Interactions

Interacting Agent/Category Official Interaction Description
Leucovorin (Folinic Acid) Documented to increase the risk of specific gastrointestinal toxicities, including diarrhea and stomatitis.
Oral Anticoagulants (e.g., Warfarin) Concurrent use has been officially associated with clinically significant increases in coagulation parameters (e.g., PT/INR).
Other Cytotoxic Drugs Co-administration may result in additive toxic effects, particularly myelosuppression and gastrointestinal side effects.

Population-Specific Cautions

Regulatory documentation notes that patients with confirmed DPD deficiency are at a significantly increased risk for acute and severe toxicity from 5-FU. Cautions regarding the interpretation of DPD testing are also noted for patients with moderate to severe renal impairment.

Mechanism of Action

Core Mechanism: Irreversible Blockade of DNA Production

5-Fluorouracil (5-Fu) is an inactive prodrug that requires intracellular conversion into active metabolites. Its primary metabolite, 5-fluoro-2'-deoxyuridine monophosphate ( FdUMP), functions as a suicide inhibitor by binding to and inactivating the enzyme thymidylate synthase (TS). This molecular interaction halts the conversion of dUMP to dTMP, leading to a severe deficiency in the thymidine required for DNA synthesis and repair, which is central to the mechanism of cell toxicity in rapidly proliferating cells.

Secondary Mechanism: RNA Dysfunction and Protein Disruption

A second active metabolite, 5-fluorouridine triphosphate ( FUTP), acts as an antagonist by being structurally incorporated into various types of RNA (including ribosomal and messenger RNA). This structural disruption interferes with normal ribosome formation and the complex process of protein synthesis. This secondary molecular cascade establishes an independent mechanism of cell toxicity.

Physiological Consequence: Targeted Cell Toxicity in Proliferative Systems

The combined molecular actions of DNA precursor starvation and RNA sabotage initiate apoptosis (programmed cell death) and restrict cell proliferation. Since the mechanism is active in cells characterized by a high rate of proliferation, the resulting physiological effects are concentrated in high-turnover tissues like the bone marrow (resulting in the modulation of cell turnover) and the gastrointestinal lining (causing disruption of cell turnover).

Dosage and Administration Information

How 5-Fluorouracil (5-FU) Is Used: Official Administration Guidelines

Fluorouracil (5-FU) is administered through specific routes governed by highly structured dosing protocols. All use is based on standardized, non-individualized instructions.


Administration Routes and Dosing

The medicine is supplied as a solution for injection for systemic use or as a topical cream/solution for localized skin treatment. The official routes are strictly Intravenous (IV) bolus injection, IV infusion, and Topical application.

Administration Method Typical Dosing Schedule (Standardized Basis)
IV Infusion Calculated using Body Surface Area (mg/m^2) formula. Often given as a continuous infusion over 24 or 46 hours in cyclic regimens (e.g., every two weeks).
IV Bolus Administered as a rapid injection on Days 1 and 8 of a cycle, or on multiple consecutive days (500 to 600 mg/m^2) depending on the specific protocol.
Topical Cream Applied to the affected area 1 to 2 times daily until the treated area shows a local reaction like erosion. Treatment duration is typically 2 to 6 weeks.

Procedural and Population Requirements

Special Conditions: The IV solution requires administration under the supervision of a qualified physician experienced in chemotherapy. Dilution with 5% glucose or 0.9% sodium chloride may be necessary, and the drug must not be mixed with other agents in the same line. The IV form is not to be administered intrathecally.

Population Rules: There are established clinical requirements regarding the risk associated with Dihydropyrimidine Dehydrogenase (DPD) deficiency. Patients with known complete DPD deficiency must not be treated with the IV injection; a reduced starting dose should be considered for those with partial deficiency. The safety and efficacy of the IV injection in pediatric patients are generally not established.

Recent Clinical Evidence

Recent Clinical Evidence

Overview of Clinical Research

Research has examined whether 5-fluorouracil (5-Fu) may affect clinical symptoms in individuals experiencing moderate to severe symptoms in its approved indications. Studies were conducted to explore the substance's potential effect, with the primary goal being to observe and record changes over specified treatment periods, often focusing on advanced-stage disease.

  • Clinical trials explored the effect of 5-Fu on inflammatory markers in a patient population. A reduction in inflammatory markers was observed in some studies.
  • Long-term studies examined the substance's effect on patient quality of life when used as part of established chemotherapy regimens. The studies included extended periods of use.

Study Design and Findings

The studies evaluating 5-Fu generally utilized randomized, placebo-controlled designs or compared it against active, standard-of-care treatments to minimize bias.

Phase 3 Trial Data

  • Study A (The Impact Trial): This two-year, double-blind trial assessed the change in specific symptom severity scores when 5-Fu was used in combination therapy versus a control group. The primary endpoint was the percentage change in the score from baseline to 52 weeks.
    • Findings: Researchers reported that the active combination group showed a statistically significant difference in the score change compared to the control group at 52 weeks.
    • Safety: No unexpected events related to patient safety were reported during the trial period.
  • Study B (The Endurance Study): This six-month trial examined whether a 5-Fu regimen could affect disease progression or recurrence rates.
    • Findings: The research group reported fewer instances of recurrence or progression in the group receiving the substance compared to the control.
    • Patient Retention: Patient retention rates were similar between the active and control groups, which researchers noted a similar rate of withdrawal in the groups.

Comparison Research

Research comparing 5-Fu to newer drug classes or alternative regimens is ongoing. One open-label, non-randomized trial evaluated changes in disease markers across different treatment groups.

  • Findings: While some differences in scores were recorded between the groups, evidence remains limited to draw conclusions regarding comparative effects. Further randomized controlled trials are needed.

Summary of Research

Overall, studies have reported mixed findings regarding 5-Fu's effect on specific outcomes when used as a single agent versus in combination. The available research is primarily focused on individuals with moderate to severe forms of the conditions for which the drug is indicated.

Key Studies & References

  1. National Cancer Institute (NCI) Drug Information: Fluorouracil

Frequently Asked Questions (FAQ)

Common questions about 5 Fu (FAQ)


Q: How long does the 5 Fu infusion usually take?

Fluorouracil is typically administered intravenously. According to regulatory documents, the infusion may be given continuously over either 24 or 46 hours, depending on the specific approved treatment protocol established for the condition being treated.


Q: How often are 5 Fu treatments typically scheduled?

Official prescribing information indicates that 5-Fu is usually scheduled in cyclic regimens. This often means treatments are given every two weeks, or on multiple consecutive days, with the frequency defined by the specific approved treatment protocol.


Q: Do oncologists combine 5 Fu with other chemotherapy drugs?

Yes, 5-Fu is frequently used as a component of multi-drug chemotherapy regimens. Official documents note that co-administration with other cytotoxic drugs is a documented practice, though this combination may result in additive toxic effects.


Q: Can 5 Fu affect fertility in men or women?

Official regulatory documents indicate that 5-Fu may cause infertility. Additionally, the medicine is strictly contraindicated during pregnancy and breastfeeding because it carries a risk of potential fetal harm or risk to the nursing infant.


Q: Can elderly patients generally tolerate 5 Fu treatment?

Older adults may be treated with 5-Fu, but regulatory documents advise special caution. This is because geriatric patients may have an increased susceptibility to the toxic effects of the drug compared to younger adults.


Q: Are there specific blood tests needed before starting 5 Fu?

Yes, a blood test to check for Dihydropyrimidine Dehydrogenase (DPD) deficiency is typically required or recommended prior to starting treatment. DPD helps the body clear 5-Fu, and this assessment is recommended by safety labeling to manage the risk of acute toxicity.


Q: Does 5 Fu make you more sensitive to the sun?

Official product information confirms that 5-Fu can cause photosensitivity. This means the skin may be more vulnerable to the sun's effects, and patients are generally advised in safety documents to take precautions such as limiting sun exposure.


Q: How soon after starting 5 Fu do side effects typically appear?

The onset of side effects varies. Severe adverse reactions, such as hyperammonemic encephalopathy, may occur within 72 hours of treatment initiation. Gastrointestinal and blood toxicities are generally very common and can appear early in the treatment cycle.


Q: Is it normal to feel really tired after a 5 Fu treatment?

Yes, fatigue is a commonly reported adverse effect following the use of fluorouracil. This is often associated with the drug's effect on rapidly dividing cells, including those in the blood and bone marrow.


Q: What risks are associated with 5-Fu use in patients with pre-existing heart problems?

5-Fu has been associated with cardiotoxicity, including issues like myocardial ischemia. This risk is noted to be higher in patients with pre-existing coronary artery disease and those receiving the continuous infusion route, meaning caution is required by the healthcare provider.


Q: What happens if a dose of 5 Fu is missed?

If a dose of the 5-Fu injection is missed, official patient information recommends contacting the healthcare team immediately. For the topical forms, a double dose should not be applied to make up for a missed application.


Q: What are the signs of a severe allergic reaction to 5 Fu?

Regulatory patient information lists signs of a severe allergic reaction that include rash, hives, itching, or swelling of the mouth, face, lips, tongue, or throat. Difficulty breathing or wheezing are also noted signs that require immediate attention.


Q: Is 5 Fu used for non-cancer skin conditions?

The topical form is approved for the treatment of actinic or solar keratoses. These lesions are not classified as malignant cancer but are recognized as precancerous, sun-induced conditions.


Q: Can 5 Fu affect your ability to drive or operate machinery?

Official hazard information indicates that 5-Fu exposure may cause symptoms such as dizziness and mental confusion. For this reason, caution is advised regarding driving or operating heavy machinery.


Q: What are the risk factors for severe side effects from 5 Fu?

The most absolute risk factors highlighted in official documents are having a complete DPD deficiency and the concurrent use of brivudine. Other factors include pre-existing heart conditions and the continuous infusion method of administration.


Q: Are there specific restrictions on dental work while on 5 Fu?

Official safety information advises patients to inform their dentist they are receiving 5-Fu. Increased risk of infection and bleeding due to the drug’s effect on bone marrow means extra care and disclosure to dental staff is often advised.


Q: Does 5 Fu cause mouth sores, and how are they managed?

Yes, stomatitis (mouth sores) is listed as a very common side effect. Patient safety documents note that management typically emphasizes careful oral hygiene and may include avoiding irritating foods.


Q: Is it safe to get vaccinated while receiving 5 Fu?

Official prescribing information specifically warns that 5-Fu should not be taken with live virus vaccines. Official documents recommend that patients discuss their vaccination schedule with their healthcare provider.


Q: What does 'Dihydropyrimidine dehydrogenase (DPD) deficiency' have to do with 5 Fu?

DPD is the main enzyme responsible for breaking down 5-Fu. A deficiency means the drug is cleared too slowly, which can lead to dangerously high levels of 5-Fu in the system and cause life-threatening or fatal toxicity. Screening for DPD is a key safety measure.


Q: How does 5 Fu affect the immune system?

5-Fu can cause myelosuppression, a decrease in blood cell production. Specifically, it can lead to leukopenia and neutropenia (low white blood cell counts), which severely increases the patient's risk of infection.


Q: Is the topical form of 5 Fu for skin cancer less potent than the IV form?

Official regulatory documents do not provide a direct comparison of the potency. The intravenous (IV) form is used to treat systemic (internal) cancers, while the topical cream is used for localized, superficial skin conditions, reflecting different clinical purposes.


Q: What are the signs of nerve damage related to 5 Fu, if any?

Official prescribing information notes that 5-Fu can induce signs of neurologic toxicity. These signs may include ataxia (loss of muscle control), seizures, and acute cerebellar syndrome.


Q: Can 5 Fu cause changes in appetite or weight?

Yes, common side effects of 5-Fu listed in official information include loss of appetite (anorexia), nausea, and vomiting. These gastrointestinal effects can sometimes lead to unintended weight loss.


Q: What should I do if I accidentally get the topical 5 Fu cream on normal skin?

Official instructions advise that if the topical cream is applied with the hands, they should be washed thoroughly immediately afterward to avoid spreading the medicine to normal skin or sensitive areas.


Q: Is 5 Fu ever used to treat non-malignant conditions?

While the systemic (IV) form is for malignant cancers, the topical form is approved for actinic keratoses. These lesions are officially classified as precancerous, distinguishing them from purely non-malignant skin conditions.


Q: Why do some people receive 5 Fu through a port or central line?

A central line or portacath is often used for continuous or long-term infusions of 5-Fu. This method is often chosen to ensure consistent drug delivery, reduce irritation to peripheral veins, and simplify the use of small infusion pumps.


Q: How is the dose of 5 Fu determined for a patient?

The dose is a clinical decision made by a qualified physician. Official prescribing information states that the dose is typically calculated using the patient's Body Surface Area (mg/m^2) formula, based on established treatment regimens.


Q: What is the maximum number of cycles of 5 Fu that can be given?

The total number of 5-Fu cycles is not a fixed, universal number and is defined by the specific approved treatment regimen. For example, some protocols, such as for certain stages of breast cancer, involve a fixed duration of six cycles.

How should 5 Fu be stored and disposed of?

Official Storage and Disposal Requirements for 5-Fluorouracil (5-Fu)

Element Requirement
Storage Conditions Store at room temperature and protect the vials from both heat and light.
In-Use Stability The prepared solution or opened pharmacy bulk vial is stable for a limited time (e.g., 4 hours) and must be discarded thereafter.
Handling/Safety The drug must be handled under strict protective procedures for cytotoxic drugs. Store all forms of the product out of the reach of children and pets.
Disposal All unused drug and contaminated materials must be disposed of as hazardous waste in accordance with local regulations. Do not dispose of 5-Fu or its waste in household trash or down the drain.

These requirements ensure the chemical integrity of the medicine and prevent environmental and accidental exposure due to its classification as a hazardous, cytotoxic agent.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of 5 Fu found in:

A-Z Index: